Practice

Review: Biosimilar-to-Biosimilar Switching Is Safe, Effective

August 9th 2022

By Skylar Jeremias

A systematic review found that patients who were switched from one biosimilar to another did not experience a change in clinical outcomes or an increase in adverse events.

Vizient Market Outlook Report Predicts Trends for Adalimumab Biosimilars in 2023

August 2nd 2022

By Skylar Jeremias

Article

Vizient’s Pharmacy Market Outlook report offers predictions on how the emergence of adalimumab biosimilars in 2023 will affect the biosimilar industry and what actions should be taken in advance to ensure biosimilar adoption.

Not So Different: How Health Policies May Take Shape in a Post-Humira-Exclusive Adalimumab Market

July 24th 2022

By Skylar Jeremias

Podcast

On this podcast episode, The Center for Biosimilars spoke with Chronis Manolis from UPMC Health Plan to discuss how health care policies may shift as adalimumab biosimilars referencing Humira come to market in 2023, including how providers and payers can ensure equitable access.

Contributor: The Trouble With IP for Digital Health and Precision Medicine

July 18th 2022

By Ha Kung Wong, JD

Article

Two experts in biosimilar intellectual property (IP) law break down the issues that digital health and precision medicine face with IP and the history of case law that has created the current landscape.

Contributor: Good Bait and Fair Switch—Biosimilar Interchangeability, Substitution, and Choice

July 11th 2022

By Ivo Abraham, PhD

Article

Ivo Abraham, PhD, chief scientist of Matrix45 and a member of The Center for Biosimilars® Advisory Board, explains the difference between biosimilar interchangeability and substitution and weighs in on whether switching studies are necessary.

Survey: Most Patients Received Inadequate Information About Switching to a Trastuzumab Biosimilar

July 9th 2022

By Deana Ferreri, PhD

Article

A survey study found that many patients with breast cancer reported receiving inadequate information regarding switching from Herceptin to a trastuzumab biosimilar, with some patients reporting that they were never told a switch occurred or what a biosimilar was.

Medicines for Europe Recommends Off-Patent Drugs to Strengthen European Health Systems

July 5th 2022

By Skylar Jeremias

Article

During its annual conference in Sitges, Spain, Medicines for Europe recommended policy reforms for strengthening European health systems, including the use of off-patent medications like biosimilar and generic drugs.

Consulting With Clinical Pharmacists May Help Boost Biosimilar Adoption

June 28th 2022

By Skylar Jeremias

Article

Having patients meet with a clinical pharmacist before a rheumatologist could help improve biosimilar adoption rates and mitigate the nocebo effect in patients with chronic diseases, according to a recent study.

How Will Payers Manage Multiple Adalimumab Biosimilars? Jeffrey Casberg Explains

June 22nd 2022

By Skylar Jeremias

Video

Jeffrey Casberg, vice president of pharmacy at IPD Analytics, discussed the different options that payers have to manage the growing number of biosimilars referencing Humira (adalimumab) that are expected to enter the market in 2023 and beyond.

ASCO Studies Assess Biosimilar Substitution, Adoption in Oncology Practices

June 16th 2022

By Skylar Jeremias

Article

Abstracts from the American Society of Clinical Oncology (ASCO) annual meeting took a look at the impact biosimilar substitution and increased biosimilar adoption had on spending within practices participating in value-based payment models and the Oncology Care Model.